Thursday, November 12, 2026
ExploreSearch
Via News
Markets

Aspen Group Stock Is 2.77% Down So Far On Friday

ViaNews Editorial Team

December 4, 2020

Aspen Group Stock Is 2.77% Down So Far On Friday
Shares of Aspen Group dropped 2.77% to $11.41 at 14:09 EST on Friday, following yesterday's upward trend. The Nasdaq Stock Market is jumping 0.56% to $12,446.80, following yesterday's upward trend, on what at the moment seems, a somewhat positive trend trading session today. Aspen Group's last close was $11.74, 15.34% under its 52-week high of $13.16.

Aspen Group's Sales

The company's growth estimates for the current quarter is a negative 33.3% and positive 75% for the next.

Aspen Group's Revenue

Year-on-year quarterly revenue growth grew by 46.4%, now sitting on 53.87M for the twelve trailing months.

Aspen Group's Stock Top and Bottom Yearly Value

Aspen Group's stock is valued at $11.41 at 14:09 EST, way under its 52-week high of $13.16 and way higher than its 52-week low of $4.65.

Aspen Group's Moving Average

Aspen Group's worth is above its 50-day moving average of $10.96 and above its 200-day moving average of $10.45.

Categories

Markets

Tags

Stock MarketStockWall StreetStock PriceStock Market NowNASDAQMarket SessionIXICThe Nasdaq Stock MarketAspen GroupASPUStock Price Down
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com